From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

Related Keywords

Toronto ,Ontario ,Canada ,Ozempic Wegovy ,Holden Thorp ,Anne Claude Gingras ,Mounjaro Zepbound ,Bbdc Novo Nordisk ,Daniel Drucker ,Lunenfeld Tanenbaum Research Institute ,Sinai Health ,Research At Sinai Health ,Canada Gairdner International Award ,University Of Toronto ,Tanenbaum Research ,Chi Kin ,Cell Metabolism ,Novo Nordisk Chair ,Incretin Biology ,Temerty Faculty ,Gairdner International Award ,Science Magazine ,Brain ,Glp 1 ,Flood ,Blood Sugar ,Fell ,Hronic ,Diabetes ,Drugs ,Glp1 ,Glucagon ,Heart ,Heart Disease ,Ormone ,Immune System ,Inflammation ,Kidney ,Liver ,Medicine ,Metabolism ,Eceptor ,Research ,Type 2 Diabetes ,Weight Loss ,